An increasing amount of evidence suggests that the FDA-approved antibiotic minocycline might have neuroprotective effects in animal models of various neurodegenerative disorders, and Gordon et al.

A low-dose (40 mg) modified formulation of minocycline hydrochloride (DFD-29) was better tolerated and more effective than doxycycline and placebo in patients with moderate to severe ...